Japan Intravenous Solution Market

Japan Intravenous Solution Market Insights Forecasts to 2035

• The Japan Intravenous Solution Market Size Was Estimated at USD 685.3 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 9.81% from 2025 to 2035
• The Japan Intravenous Solution Market Size is Expected to Reach USD 1918.2 Million by 2035

According to a research report published by Decision Advisors & Consulting, the Japan Intravenous Solution Market size is anticipated to reach USD 1918.2 Million by 2035, growing at a CAGR of 9.81% from 2025 to 2035. Japan Intravenous Solution Market growing due to an ageing society will lead to an increasing number of chronic illnesses such as diabetes and cancer, leading to an increase in people who require treatment.

Market Overview

The Japanese intravenous (IV) solutions industry includes the field involved in manufacturing and distributing injectable liquids utilized for hydration, nutritional supplementation and drug delivery within Japan. A sterile aqueous mixture containing water, electrolytes, sugars or pharmaceuticals delivered into veins via IV infusion allows patients to obtain rapid hydration. A sterile IV infusion offers entry to the bloodstream facilitating hydration, nutritional assistance or prompt therapy, for diseases or injuries. In medical environments intravenous (IV) therapy is frequently utilized to deliver hydration or nutrition to patients with compromised cognitive function who cannot intake nourishment orally. IV therapy is also employed as a technique for delivering medication and other treatments aimed at rectifying electrolyte disturbances (such as blood products, electrolytes). The Japan intravenous solution market is propelled by innovations in secure intravenous delivery systems heightened government initiatives to enhance healthcare quality and the adoption of technology, in digital transformation efforts. This market also characterised by rising prevalence of chronic diseases and demand for IV therapies, while challenges include high operational costs and stringent regulations. There is also a growing trend toward disposable IV systems and smart infusion pumps integrated with technology like EMRs and remote monitoring.

The Ministry of Health, Labour and Welfares (MHLW's) role is crucial in setting standards and supporting the development of the pharmaceutical and medical device industries, including IV solutions, through various policies and funds.

Report Coverage

This research report categorizes the market for the Japan intravenous solution market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan Intravenous Solution Market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan Intravenous Solution Market.

Driving Factor

Japan intravenous solution market is driven by increasing prevalence of chronic illnesses and types of surgical procedures among an ageing population, as well as an increase in government health expenditures and developments in the field of medical devices has spurred the growth of the Japanese market for intravenous (IV) solutions. A greater demand for nutritional and rehydrated therapies as a result of malnourishment and dehydration expansion of the market through home and ambulatory health care and increased public awareness of alternative treatments, such as intravenous vitamin C therapy as a treatment for some forms of cancer, that are available using IV solutions.

Restraining Factor

Japan Intravenous Solution Market is restrained by strict regulations, rising raw material and production costs, safety and contamination issues and limited reach to remote areas have affected companies. The unique challenges presented by Japan's demographic trends an increasingly older adult population combined with an ever-declining fertility rate.

Market Segmentation

The Japan intravenous solution market is categorized by product and nutrients.

By Product

The Japan intravenous solution market is segmented by product into total parenteral nutrition and peripheral parenteral nutrition. Among these, the total parenteral nutrition is dominant in Japan intravenous solution market due to the prevailing trend of TPN usage in the country is a direct result of numerous occurrences, including an ageing population, the existence of significant numbers of individuals with chronic diseases, and the high level of sophistication within the country's health care delivery system.

By Nutrients

The Japan intravenous solution market is segmented by nutrients into carbohydrates, vitamins & minerals, single-dose amino acids, parenteral lipid emulsion and others. Among these, the single-dose amino acids are dominant in Japan intravenous solution market due to their safety and convenience, which help to streamline administration and decrease the risk of contamination. This ease of use leads to more tailored solutions to the nutritional needs of patients based upon their unique situations, which ultimately produces better patient outcomes, particularly in oncology patients experiencing malnutrition and older adults.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan intravenous solution market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

The Key Companies

• Otsuka Pharmaceutical Factory, Inc.
• Terumo Corporation
• Nipro Corporation
• JMS Co., Ltd.
• Mitsubishi Chemical Group Corp.
• Asahi Kasei Corp.
• Daiichi Sankyo Co. Ltd.
• Astellas Pharma Inc.
• Fujifilm Corporation
• Fukuda Denshi
• Other

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In May 2025: Otsuka Pharmaceutical Factory and ICU Medical completed a joint venture, combining their expertise to expand into the North American IV solution market.
• In May 2025: ICU Medical Inc. (NASDAQ: ICUI) and Otsuka Pharmaceutical Factory, Inc. announced the formation of Otsuka ICU Medical LLC, a joint venture designed to strengthen IV-solution supply-chain resiliency and accelerate innovation in the North American market. The new venture combines ICU Medical’s commercial and distribution expertise with Otsuka’s global IV-solutions manufacturing capabilities.

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Decision Advisors has segmented the Japan Intravenous Solution Market based on the below-mentioned segments:

Japan Intravenous Solution Market, By Product

• Total Parenteral Nutrition
• Peripheral Parenteral Nutrition

Japan Intravenous Solution Market, By Nutrients

• Carbohydrates
• Vitamins & Minerals
• Single-dose Amino Acids
• Parenteral Lipid Emulsion
• Others

Frequently Asked Questions (FAQs)

Q: What is the Japan intravenous solution market size?

A: Japan Intravenous Solution Market size is expected to grow from USD 685.3 million in 2024 to USD 1918.2 million by 2035, growing at a CAGR of 9.81% during the forecast period 2025-2035.

Q: Who are the key players in the Japan intravenous solution market?

A: The key players include Otsuka Pharmaceutical Factory, Inc., Terumo Corporation, Nipro Corporation, JMS Co., Ltd., Mitsubishi Chemical Group Corp., Asahi Kasei Corp., Daiichi Sankyo Co. Ltd., Astellas Pharma Inc., Fujifilm Corporation, Fukuda Denshi and Other

Q: What factors restrain the Japan intravenous solution market?

A: Japan Intravenous Solution Market is restrained by strict regulations, rising raw material and production costs, safety and contamination issues and limited reach to remote areas have affected companies. The unique challenges presented by Japan's demographic trends an increasingly older adult population combined with an ever-declining fertility rate.